IL1B and Alzheimer disease: The level of IL-1β was decreased in groups receiving β-asarone (20 mg/kg, 30 mg/kg) treatment compared to the AD model group (171.7 ± 25.10 versus 203.5 ± 39.50 pg/mL, 163.3 ± 18.80 versus 203.5 ± 39.50 pg/mL, P < 0.01, P < 0.01).